Todas las investigaciones
ReclutamientoExploratorio terapéutico (Fase II)Intervencionista

A Phase 2, Randomized, Open-Label, 24-Week Study to Assess the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of GLM101 Administered Intravenously to Adult, Adolescent and Pediatric Participants with PMM2-CDG

This research study is looking into a new medicine called GLM101 for individuals with a rare genetic condition called PMM2-CDG. It's a 'Phase 2' study, which means we're still in the earlier stages of figuring out how well the medicine works and if it's safe. For 24 weeks, researchers will give GLM101 as an injection into the vein to see how the body handles it and its effects. They will closely monitor participants to understand if the medicine helps with movement difficulties, which are common in PMM2-CDG. The main goal is to see if it improves coordination and balance, while also checking for any side effects.

De un vistazo

Estado
Reclutamiento
Fase
Exploratorio terapéutico (Fase II)
Patrocinador
Glycomine Inc.
Objetivo de inscripción
19
Inicio
22 Abr 2024

¿De qué trata este estudio?

This research study is an important step in trying to find better treatments for PMM2-CDG, a rare genetic disorder that can affect many parts of the body, especially movement and coordination. The study is called 'Phase 2', which means it's one of the first times this new medicine, GLM101, is being tested in a larger group of people. We're looking to understand how the medicine works in the body, confirm it's safe to use, and see if it can help improve some of the challenges people with PMM2-CDG face, particularly with their movement.

Over 24 weeks, participants will receive the study medicine, GLM101, through a drip into their vein. During this time, the research team will regularly check their health and how their body is responding to the medicine. A key part of this study is checking for changes in movement and coordination using a special scoring system. We'll also be very carefully monitoring for any side effects or changes in their general health, including blood tests and heart checks.

The information gathered from this study is crucial. It will help us understand if GLM101 could be a promising new treatment option for PMM2-CDG in the future. If the results are positive, it means we could move closer to making a real difference for people living with this condition.

Puntos clave

  • This study tests a new medicine, GLM101, for PMM2-CDG.
  • It aims to check if GLM101 is safe and helps with movement.
  • Participants will receive the medicine through an IV drip for 24 weeks.
  • Regular health checks, blood tests, and movement assessments will be done.
  • The study is for adults aged 18 and over with PMM2-CDG.
  • This is an 'open-label' study, so you will know you are receiving the active drug.

¿Quién puede ser elegible?

To join this study, participants must be at least 18 years old. Both men and women are welcome to take part in the research.

Because this study focuses specifically on PMM2-CDG, participants will need to have a confirmed diagnosis of this condition. The study is looking for adults who are able to complete the study assessments.

There might be other health requirements or reasons why someone can't join, which the study doctor will discuss if you're interested. This is to make sure the study is safe for everyone involved and that the results are clear.

¿Podría este estudio ser adecuado para ti?

Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.

  1. I have been diagnosed with PMM2-CDG.
  2. I am 18 years old or older.
  3. I am able to attend regular clinic appointments.
  4. I am not currently pregnant or breastfeeding (if applicable).
Responde cada pregunta para ver tu resultado.

¿En qué consiste la participación?

If you decide to take part in this study, you would receive the study medicine, GLM101, through an intravenous (IV) drip. This means the medicine will be delivered directly into your bloodstream through a small tube in your arm. The treatment period will last for 24 weeks, and during this time, you will have regular visits to the clinic.

During these visits, the research team will perform various checks. These include physical examinations, taking blood and urine samples, checking your heart with an ECG (electrocardiogram), and monitoring your vital signs like blood pressure and heart rate. They will also assess your movement and coordination using specific tests. You'll be asked about how you're feeling and if you've experienced any side effects. After the 24 weeks of treatment, there will be follow-up visits to ensure your continued well-being. The total duration of your involvement, including follow-up, will be explained by the study team.

Riesgos y beneficios potenciales

Taking part in a study like this might offer potential benefits, such as access to a new medicine that isn't yet widely available, and helping advance medical science to possibly find new treatments for PMM2-CDG. However, like all medicines, GLM101 might have side effects, including reactions where the drip is given, or other unexpected effects. The research team will carefully monitor you for any problems. You have the right to withdraw from the study at any time, for any reason, without it affecting your medical care.

Ubicaciones (1)

Algunas ubicaciones de los sitios son aproximadas. Estamos mejorando esto — por favor verifique con el equipo de prueba antes de viajar.
  • —
    No verificado
    España

Preguntas comunes

What is PMM2-CDG?

PMM2-CDG is a rare genetic condition that can affect many parts of the body, often causing problems with movement and coordination.

What does 'Phase 2' mean?

Phase 2 means this is one of the initial stages of testing a new medicine in people. Researchers are looking closely at its safety and how well it works.

¿Cómo se administrará el medicamento?

The medicine, GLM101, will be given through a drip into a vein, usually in your arm.

¿Cuánto dura el estudio?

The active treatment part of the study lasts for 24 weeks, with follow-up appointments after that.

Will I know if I'm getting the real medicine?

The study description mentions 'open-label', which means both you and the study team will know you are receiving GLM101, not a dummy treatment.

Cómo obtener más información

Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.

¿Interesado en participar?

Registra tu interés

Comparte tus detalles y el equipo de investigación para "A Phase 2, Randomized, Open-Label, 24-Week Study to Assess t…" se pondrá en contacto contigo si puedes ser elegible. Siempre habla con tu médico antes de aceptar participar.

Discusión

Discusión comunitaria

Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.